Company Filing History:
Years Active: 2017-2019
Title: Steven P. Piccoli: Innovator in Antibody Development
Introduction
Steven P. Piccoli is a notable inventor based in Princeton, NJ (US). He has made significant contributions to the field of immunology, particularly in the development of antibodies that interact with polyethylene glycol (PEG). With a total of 2 patents, his work has implications for therapeutic proteins and their pharmacokinetic properties.
Latest Patents
Piccoli's latest patents focus on methods of using human Fc-bearing IgG antibodies to PEG. His research addresses the immunogenicity of PEG, which is commonly used in food and cosmetics. The presence of PEG can lead to the development of pre-existing anti-PEG antibodies in humans. His patents provide both polyclonal and monoclonal antibodies that are reactive to PEG, which are essential for developing immunogenicity assays to detect anti-drug antibodies. These antibodies are engineered to exhibit preferential binding based on the size of PEG, with molecular weights ranging from 350 daltons to 40 kD.
Career Highlights
Steven P. Piccoli is currently associated with Bristol-Myers Squibb Company, where he continues to advance his research in antibody development. His work is crucial in enhancing the therapeutic applications of PEG-conjugated proteins.
Collaborations
Some of his notable coworkers include Murli Krishna and Alexander T. Kozhich, who have collaborated with him on various projects related to immunogenicity and antibody engineering.
Conclusion
Steven P. Piccoli's innovative work in the field of antibody development has the potential to significantly impact therapeutic practices involving polyethylene glycol. His contributions are vital for improving the safety and efficacy of therapeutic proteins.